<DOC>
	<DOCNO>NCT00920543</DOCNO>
	<brief_summary>The purpose study determine whether asthma control reduce bronchial hyperresponsiveness could achieve maintain low dose inhaled corticosteroid ADVAIR DISKUS twice-daily FP twice-daily adult adolescent subject persistent asthma</brief_summary>
	<brief_title>GSK BHR Study ( Sont )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Asthma diagnosis Controller medication moderate inhale corticosteroid dose Evidence reversibility Lifethreatening asthma Asthma instability Concurrent respiratory disease Drug allergy Respiratory tract infection Systemic corticosteroid use Immunosuppressive medication use Positive pregnancy test Tobacco use Site affiliation</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>